Kura’s $150M PIPE; Lilly’s investment in Prism BioLab; Annovis delays PhIII data, citing ‘data cleaning’
2024-01-24
IPO
Plus, news about IMU Biosciences, ZWI Therapeutics and Sagimet Biosciences:
Kura Oncology’s $150M PIPE:
The biotech
is raising
funds from a stock sale to its existing investors, including EcoR1 Capital, an affiliate of Deerfield Management and Suvretta Capital Management. It’s selling at $17.25 a share, a 29% premium to Kura’s closing price on Tuesday. The news sent the San Diego biotech’s stock
$KURA
up nearly 50% Wednesday morning. The $150 million will likely extend Kura’s runway out to 2027. The company expects to share data next week from a combination study of its lead candidate, ziftomenib, in acute myeloid leukemia.
— Lei Lei Wu
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
靶点
-来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。